Novartis wins Us Ok for biosimilar version of Amgen's Enbrel

Novartis wins Us Ok for biosimilar version of Amgen's Enbrel


U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world. The Food and Drug Administration cleared the near-copy of the drug, dubbed Erelzi, developed by Swiss drug giant Novartis, which would not disclose the planned list price for the drug.



from Biotech News